The China ATTR (Transthyretin Amyloidosis) Therapeutics market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
The diagnosis and treatment of rare diseases are an important public health issue and a challenge for medical care in China. The prevalence rate of ATTR (Transthyretin Amyloidosis) disease in China is 1997 people per 1,00,000. With its enormous population, disparate geography and socioeconomic inequalities, China faces considerable obstacles in improving the standard of care for patients who are affected by ATTR (Transthyretin Amyloidosis) disease.
China is the growing market for ATTR (Transthyretin Amyloidosis) disease due to enormous population and increasing aging population leads to increase in China’s Prevalence rate 1997 people per 1,00,000. Faster adaptation to healthcare technology, various government policies such as investing in the R&D for developing the new treatment methods, prioritized approval process by China FDA, research funding in rare diseases, tax reduction, collaboration with international communities, Reimbursement policies, and government awareness programs are leading to growth of ATTR (Transthyretin Amyloidosis) therapeutics.
There are some restraining factors for growth of ATTR (Transthyretin Amyloidosis) therapeutics market in China such as absence of official legislation, high rate of misdiagnosis and limited funding for high-cost drugs.